Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2050 of 2051 entries
View as:

Sitagliptin Added-on to Insulin Study (0431-051)

Phase: N/A Priority: Normal
NCT ID: NCT00395343 Org: User:
Start: 12/11/06 End: 10/13/08 Due: 10/13/09

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

Phase: N/A Priority: Normal
NCT ID: NCT05700734 Org: User:
Start: 04/17/23 End: 02/14/24 Due: 02/14/25

Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)

Phase: N/A Priority: Normal
NCT ID: NCT00230243 Org: User:
Start: 03/31/97 End: 09/30/02 Due: 09/30/03

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Phase: N/A Priority: Normal
NCT ID: NCT00759109 Org: User:
Start: 03/31/02 End: 11/30/09 Due: 11/30/10

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Phase: N/A Priority: Normal
NCT ID: NCT01556451 Org: User:
Start: 04/30/12 End: 10/31/12 Due: 10/31/13

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Phase: N/A Priority: Normal
NCT ID: NCT03924869 Org: User:
Start: 06/25/19 End: 01/20/25 Due: 01/20/26

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03881111 Org: User:
Start: 01/21/19 End: 05/11/22 Due: 05/11/23

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Phase: N/A Priority: Normal
NCT ID: NCT03675737 Org: User:
Start: 11/08/18 End: 03/03/25 Due: 03/03/26

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Phase: N/A Priority: Normal
NCT ID: NCT01860729 Org: User:
Start: 05/13/13 End: 08/20/15 Due: 08/20/16

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Phase: N/A Priority: Normal
NCT ID: NCT04191096 Org: User:
Start: 02/12/20 End: 02/02/26 Due: 02/02/27

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Phase: N/A Priority: Normal
NCT ID: NCT01323855 Org: User:
Start: 03/28/11 End: 11/29/11 Due: 11/29/12

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Phase: N/A Priority: Normal
NCT ID: NCT01512667 Org: User:
Start: 01/17/12 End: 08/22/12 Due: 08/22/13

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Phase: N/A Priority: Normal
NCT ID: NCT04938830 Org: User:
Start: 11/30/21 End: 08/13/25 Due: 08/13/26

Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00917696 Org: User:
Start: 10/31/09 End: 06/30/11 Due: 06/30/12

An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)

Phase: N/A Priority: Normal
NCT ID: NCT01739348 Org: User:
Start: 11/30/12 End: 04/14/17 Due: 04/14/18

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

Phase: N/A Priority: Normal
NCT ID: NCT00559182 Org: User:
Start: 12/05/07 End: 07/09/10 Due: 07/09/11

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Phase: N/A Priority: Normal
NCT ID: NCT03903562 Org: User:
Start: 04/27/19 End: 02/28/25 Due: 02/28/26

A Study of MK-2060 in Healthy Participants (MK-2060-016)

Phase: N/A Priority: Normal
NCT ID: NCT06582602 Org: User:
Start: 10/15/24 End: 04/18/25 Due: 04/18/26

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Phase: N/A Priority: Normal
NCT ID: NCT04924101 Org: User:
Start: 07/15/21 End: 06/23/25 Due: 06/23/26

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Phase: N/A Priority: Normal
NCT ID: NCT03493542 Org: User:
Start: 08/31/18 End: 10/30/23 Due: 10/30/24

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)

Phase: N/A Priority: Normal
NCT ID: NCT01930058 Org: User:
Start: 10/02/13 End: 05/05/14 Due: 05/05/15

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Phase: N/A Priority: Normal
NCT ID: NCT05386589 Org: User:
Start: 06/14/22 End: 01/05/23 Due: 01/05/24

A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

Phase: N/A Priority: Normal
NCT ID: NCT00157872 Org: User:
Start: 01/07/04 End: 09/19/04 Due: 09/19/05

Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)

Phase: N/A Priority: Normal
NCT ID: NCT02064920 Org: User:
Start: 04/22/14 End: 07/13/16 Due: 07/13/17

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Phase: N/A Priority: Normal
NCT ID: NCT06052566 Org: User:
Start: 11/21/23 End: 12/05/24 Due: 12/05/25